Rallybio expects Avenzo merger to close Nov 20; sets $13.90/share cash distribution
#SEC #stocks #investing #RLYB #Mergers
🔗 secwatch.observer
Rallybio expects Avenzo merger to close Nov 20; sets $13.90/share cash distribution
#SEC #stocks #investing #RLYB #Mergers
🔗 secwatch.observer
On November 10, 2026, Rallybio Corporation announced that it will effect a one-for-two reverse stock split of its issued and outstanding common stock in connection with the transactions contemplated by the Agreement and Plan of Merger and Reorganization , dated as of May 31, 2026, among t...
On November 10, 2026, Rallybio Corporation announced that it will effect a one-for-two reverse stock split of its issued and outstanding common stock in connection with the transactions contemplated by the Agreement and Plan of Merger and Reorganization , dated as of May 31, 2026, among t...
https://www.stocktitan.net/news/RLYB/rallybio-announces-reverse-stock-split-of-common-stock-in-connection-kycpbigrsqz1.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/RLYB/rallybio-announces-reverse-stock-split-of-common-stock-in-connection-kycpbigrsqz1.html?utm_source=stocktitan-bluesky&utm_medium=social
Rallybio Corporation previously disclosed that, subject to the satisfaction or waiver of any outstanding closing conditions, the Company anticipated the transactions contemplated by the Agreement and Plan of Merger and Reorganization, dated as of May 31, 2026 , by and among the Company, A...
Rallybio Corporation previously disclosed that, subject to the satisfaction or waiver of any outstanding closing conditions, the Company anticipated the transactions contemplated by the Agreement and Plan of Merger and Reorganization, dated as of May 31, 2026 , by and among the Company, A...
HUNT RONALD (Insider) reported special transactions (Non-P/S).
HUNT RONALD (Insider) reported special transactions (Non-P/S).
MACKAY MARTIN (Insider) reported special transactions (Non-P/S).
MACKAY MARTIN (Insider) reported special transactions (Non-P/S).
Rallybio holders approve Avenzo merger and $13.90/share cash distribution; close expected Nov. 6
#SEC #stocks #investing #RLYB #Mergers
🔗 secwatch.observer
Rallybio holders approve Avenzo merger and $13.90/share cash distribution; close expected Nov. 6
#SEC #stocks #investing #RLYB #Mergers
🔗 secwatch.observer
As previously disclosed, on October 25, 2026, the Company’s board of directors declared a special cash distribution to its stockholders in connection with the Merger . The Company has determined that the aggregate amount of the Cash Distribution is $83.6 million, or $13.90 per share.
As previously disclosed, on October 25, 2026, the Company’s board of directors declared a special cash distribution to its stockholders in connection with the Merger . The Company has determined that the aggregate amount of the Cash Distribution is $83.6 million, or $13.90 per share.
9:30 AM ET: $WVE investor event
$RLYB conference presentation
$VKTX conference call (VK2735)
Dates from the companies' SEC filings
#Biotech #Stocks
Visit for more info: www.elixstocks.com
Educational only. Not investment advice.
9:30 AM ET: $WVE investor event
$RLYB conference presentation
$VKTX conference call (VK2735)
Dates from the companies' SEC filings
#Biotech #Stocks
Visit for more info: www.elixstocks.com
Educational only. Not investment advice.
Lieber Jonathan I (Chief Financial Officer) reported special transactions (Non-P/S).
Lieber Jonathan I (Chief Financial Officer) reported special transactions (Non-P/S).
HUNT RONALD (Insider) reported special transactions (Non-P/S).
HUNT RONALD (Insider) reported special transactions (Non-P/S).
Nash Christine A (Insider) reported special transactions (Non-P/S).
Nash Christine A (Insider) reported special transactions (Non-P/S).
Uden Stephen (Chief Executive Officer) reported special transactions (Non-P/S).
Uden Stephen (Chief Executive Officer) reported special transactions (Non-P/S).
Chung Wendy (Insider) reported special transactions (Non-P/S).
Chung Wendy (Insider) reported special transactions (Non-P/S).
Lieber Jonathan I (Chief Financial Officer) sold 599 shares at an average price of $16.0400 per common share. (Date: 2026-10-27)
Lieber Jonathan I (Chief Financial Officer) sold 599 shares at an average price of $16.0400 per common share. (Date: 2026-10-27)
As previously disclosed, on May 31, 2026, the Rallybio Corporation, a Delaware corporation , entered into an Agreement and Plan of Merger and Reorganization with Avenzo Therapeutics, Inc., a Delaware corporation , and Farmington Merger Sub, Inc., a Delaware corporation and wholly-owned su...
As previously disclosed, on May 31, 2026, the Rallybio Corporation, a Delaware corporation , entered into an Agreement and Plan of Merger and Reorganization with Avenzo Therapeutics, Inc., a Delaware corporation , and Farmington Merger Sub, Inc., a Delaware corporation and wholly-owned su...
Boudreau Helen M (Insider) reported special transactions (Non-P/S).
Boudreau Helen M (Insider) reported special transactions (Non-P/S).
Soteropoulos Paula (Insider) reported special transactions (Non-P/S).
Soteropoulos Paula (Insider) reported special transactions (Non-P/S).
Hopfner Robert Lorne (Insider) reported special transactions (Non-P/S).
Hopfner Robert Lorne (Insider) reported special transactions (Non-P/S).
Lieber Jonathan I (Chief Financial Officer) reported special transactions (Non-P/S).
Lieber Jonathan I (Chief Financial Officer) reported special transactions (Non-P/S).
Uden Stephen (Chief Executive Officer) reported special transactions (Non-P/S).
Uden Stephen (Chief Executive Officer) reported special transactions (Non-P/S).
Lieber Jonathan I (Chief Financial Officer) reported special transactions (Non-P/S).
Lieber Jonathan I (Chief Financial Officer) reported special transactions (Non-P/S).